Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and CetuximabGlobeNewsWire · Oct 15, 2026
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Oct 14, 2026
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public RelationsGlobeNewsWire · Sep 30, 2026
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Target Price of $29.50 According to AnalystsDefense World · Sep 30, 2026
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADCGlobeNewsWire · Sep 8, 2026
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?Zacks Investment Research · Aug 18, 2026Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.06 | -$0.04 | Beat |
| Apr 10, 2026 | -$0.18 | -$0.81 | Miss |
| Dec 29, 2025 | -$0.18 | -$0.18 | Beat |
| Aug 7, 2025 | -$0.18 | -$0.18 | Beat |
| Apr 30, 2025 | -$0.53 | -$0.22 | Beat |
| Feb 26, 2025 | -$0.53 | -$0.22 | Beat |